2023 World Conference on Lung Cancer (Posters)-EP12.01. Conversion to Aumolertinib in NSCLC Patients with EGFR Mutations Who Are Safety Intolerant after Osimertinib Treatment: A Retrospective Study

EP12.01. Conversion to Aumolertinib in NSCLC Patients with EGFR Mutations Who Are Safety Intolerant after Osimertinib Treatment: A Retrospective Study - PDF(Slides)

Back to course

Pdf Summary

A retrospective study conducted at Tongren City People's Hospital in China examined the conversion to Aumolertinib in patients with non-small cell lung cancer (NSCLC) who had EGFR mutations and were intolerant to Osimertinib treatment. The study aimed to assess the safety and efficacy of Aumolertinib in this patient population.<br /><br />The study included advanced NSCLC patients aged 18-75 with EGFR mutations who experienced safety intolerance after Osimertinib treatment. The primary endpoint was the 3-month conversion success rate, defined as the proportion of subjects who did not experience grade 2 hematologic toxicity or grade 3 other adverse events within 3 months of switching to Aumolertinib.<br /><br />The results showed a 100% 3-month conversion success rate, indicating that all patients tolerated Aumolertinib well without significant adverse events. The overall objective response rate (ORR) was 80%, with 2 complete responses and 10 partial responses. The disease control rate (DCR) was 100%.<br /><br />Subgroup analysis showed that patients who experienced rash or diarrhea as safety intolerances after Osimertinib treatment had ORRs of 87.5% and 100% respectively with Aumolertinib.<br /><br />During Aumolertinib treatment, only two patients experienced grade 1 adverse events, including diarrhea and mouth ulceration. No other adverse events were observed. The median progression-free survival (PFS) has not been reached yet as subjects are still being followed up.<br /><br />The study concluded that Aumolertinib is safe and effective for treating EGFR-mutation advanced NSCLC patients who have safety intolerance after Osimertinib treatment, especially for those with rash or diarrhea. The findings suggest that timely and standardized intervention for managing adverse events and switching between third-generation EGFR-TKIs may improve patient compliance, quality of life, and ultimately enhance survival benefits.<br /><br />The study authors expressed gratitude to the study participants, their families and caregivers, the study team, and all the staff involved in the trial.

Asset Subtitle

Biao Yao

Meta Tag

Speaker Biao Yao

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

retrospective study

Aumolertinib

NSCLC

EGFR mutations

Osimertinib treatment

safety

efficacy

adverse events

progression-free survival

patient compliance